William R. Sellers

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Context-dependent synthetic lethality — an emerging precision therapeutic approach

  Nature reviews. Cancer · 2026-04-23

• Abstract 3898: Profiling tumor selectivity of state- and paralog-selective RAS inhibitors through a signaling inhibition index (SII).

  Cancer Research · 2026-04-03

• Abstract 2930: Unraveling determinants of drug response: PRISM viability profiling of hundreds of oncology therapeutics reveals mediators of selectivity and mechanism.

  Cancer Research · 2026-04-03

• Abstract 4738: Pharmacological activation of PI3Kα triggers cancer cell death under metabolic stress

  Cancer Research · 2026-04-03

• Figure 2 data

  Figshare · 2026-03-27 · 1 citations

• Figure 2 data

  Figshare · 2026-03-27

• Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS

  Cell chemical biology · 2026-02-01 · 1 citations

• Figure S1 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Figure S3 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Data from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Figure S2 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Supplementary Data Legends from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Figure S4 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Figure S5 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  2026-01-02

• Abstract C039: A pan-cancer map of paralog dependencies reveals novel synthetic lethal targets and biomarker-defined vulnerabilities

  Molecular Cancer Therapeutics · 2025-10-22

• Abstract A079: Directed clonal evolution: Leveraging divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation

  Molecular Cancer Therapeutics · 2025-10-22

• RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors

  Molecular Cancer Research · 2025-10-15 · 1 citations

• Figure S11 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted CancerPreprint

  2025-09-15

• Figure S10 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted CancerPreprint

  2025-09-15

• Figure S13 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted CancerPreprint

  2025-09-15